We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | $-0.06 | — | — | $961K | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.13 | — | — | $1.76M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.31 | — | — | $4.6M |
Consensus PT $5.15 · 3 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 11. 15. | Chardan Capital | — | 의견 유지 | Buy → Buy | — | Chardan Capital: Buy |
| 2025. 08. 11. | Chardan Capital | — | 의견 유지 | Buy → Buy | — | Chardan Capital: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.21 | — | — | $3.26M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Stored first · Google News · Yahoo Finance (English)
ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) ChartMill
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor - Stock Titan
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor Stock Titan
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies Minichart
Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be - GuruFocus
Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be GuruFocus
Arbutus Biopharma Swings to Profit in Q1, Revenue Rises; Shares Up Pre-Bell